Top Industry Leaders in the Overt Hepatic Encephalopathy Market
Latest North America Microarray Companies Updates
VEDANTA BIOSCIENCES: Phase 3 trial (PEARL) evaluating VE303, a novel gut-selective antibiotic, met its primary endpoint of reducing the frequency of OHE episodes in patients with cirrhosis compared to placebo. This is a significant step towards potentially offering a new treatment option for OHE.
AXCELLA HEALTH: Positive top-line data from Phase 2b trial of AXA1665, a gut-selective antibiotic, showed a trend towards reducing OHE events and improving cognitive function in patients with cirrhosis. Phase 3 trials are planned.
SALIX PHARMACEUTICALS: Ongoing observational study evaluating the real-world effectiveness of rifaximin in preventing OHE recurrence in patients with cirrhosis. Results are expected to provide valuable insights into long-term treatment strategies.
List of North America Microarray Key companies in the market:
- Alfa Wassermann S.P.A
- Cosmo Pharmaceuticals S.P.A
- Horizon Pharma Plc.
- KannaLife Sciences, Inc.
- Ocer Therapeutics
- Rebiotix Inc.
- Spherium Biomed S.L
- Umecrine Cognition AB
- ASKA Pharmaceutical
- Mallinckrodt
- Valeant
